FDA approves Novo product for congenital Factor XIII deficiency

FDA approved a resubmitted BLA from Novo Nordisk A/S (CSE:NVO; NYSE:NVO) for Tretten cartridecacog to prevent bleeding in patients with congenital Factor XIII A-subunit deficiency, a very rare genetic...